Alumis Reports Positive Phase 3 Data With Envudeucitinib

October 09, 2026 — 07:58 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3. The company said the results reinforced the potential of envudeucitinib to become a leading oral therapy for patients with moderate-to-severe plaque psoriasis. New data showed a 54% Psoriasis Area and Severity Index 100 response rate at Week 48.

Martin Babler, CEO of Alumis, said: "With our fourth-quarter 2026 NDA submission firmly on track, our organization is focused on regulatory execution and building the foundation designed to bring this next-generation therapy to patients."

In pre-market trading on NasdaqGS, Alumis shares are up 3.49 percent to $7.21.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Alumis Reports Positive Phase 3 Data With Envudeucitinib

Tags

Latest Articles